Bolt Biotherapeutics, Inc.
BOLT · XNASCIK 1641281fmd_0HXHPATTE7ZFPMJAZYQ7PEDT5CManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 27 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | 0 | 1 | 6 | 8 | 8 | 8 |
| Research and development | 40 | 76 | 73 | 62 | 57 | 29 |
| Total operating expenses | 49 | 94 | 96 | 84 | 81 | 44 |
| Compensation and benefits | – | – | – | 30 | 24 | 14 |
| Operating income | (49) | (93) | (90) | (76) | (73) | (36) |
| Other non-operating income (expense) | (12) | (6) | 2 | 7 | 10 | 3 |
| Income before taxes | – | – | – | – | (63) | (33) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | – | (63) | (33) |
| Net income | (61) | (99) | (88) | (69) | (63) | (33) |